MedTrace Logo

Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors

NCT03453528 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1225

Last updated 2025-01-08

No results posted yet for this study

Summary

multi-centre, prospective, diagnostic trial to evaluate the Prostate-Specific Membrane Antigen (PSMA-antigen) over-expression in metastatic castration resistant prostate cancer (mCRPC) and in advanced/metastatic solid tumors patients.

Conditions

  • Prostate-specific Membrane Antigen
  • mCRPC or Advanced/Metastatic Solid Tumors

Interventions

DRUG

68Ga-PSMA

68Ga-PSMA will be injected intravenously via an indwelling catheter in an antecubital vein; (68Ga-PSMA activity: min 100 MBq - max 200 MBq, weighted activity: 2.0 MBq/Kg).

Sponsors & Collaborators

  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

    lead OTHER

Principal Investigators

  • Paola Caroli, MD · IRST IRCCS

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-04
Primary Completion
2024-12-04
Completion
2025-01-03

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03453528 on ClinicalTrials.gov